Patients can inject the medication into their thigh, abdomen, or upper arm
non-osteoporosis) were compared using independent t-tests for continuous variables and chi-square tests for categorical variables
One retrospective observational study conducted in Japan has suggested that the early administration of this compound was associated with better functional outcomes and reduce HT after AIS (245), although there is data suggesting that the use of this compound may be related to increased HT (246)
This is significantly less than the 15-25%+ average weight loss often seen with high-dose GLP-1s like semaglutide or tirzepatide
Acknowledgements This work was supported by the National Natural Science Foundation of China (21102182), the Natural Science Foundation of Jiangsu Province (BK2012760, China), Fundamental Research Funds for the Central Universities (2632018ZD09, China), and Excellent Science and Technology Innovation Team of Jiangsu Province Universities in 2015 (China)
SVIA Plastic Surgery offers a supportive, medically focused environment for safe and effective weight loss
